| Outcome Measures: |
Primary: Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue, To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in HbA1c (%) at the end of 24 weeks of double-blinded treatment., Baseline to Week 24 (prior to rescue) | Secondary: Glycemic Response Defined as HbA1c < 7.0% at Week 24, To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c \< 7.0% at the end of 24 weeks of double-blinded treatment., Week 24 (prior to rescue)|Change From Baseline to Week 24 (Prior to Rescue) in Fasting Plasma Glucose, To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to reduction in fasting plasma glucose at the end of 24 weeks of double-blinded treatment., Baseline to Week 24 prior to rescue|Change From Baseline to Week 24 (Prior to Rescue) in Area Under the Curve From 0-180 Minutes for Postprandial Glucose Response to a Meal Tolerance Test, To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 180-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment., Baseline to Week 24 prior to rescue|Glycemic Response Defined as HbA1c ≤ 6.5% at Week 24, To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects achieving a therapeutic glycemic response defined as HbA1c ≤ 6.5% at the end of 24 weeks of double-blinded treatment., Week 24 (prior to rescue)|Change From Baseline to Week 24 in 120-minute Postprandial Glucose Response to a Meal Tolerance Test, To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to change in 120-minute postprandial glucose response to a meal tolerance test at the end of 24 weeks of double-blinded treatment., Baseline to Week 24 prior to rescue|Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase, To evaluate the efficacy of the combination therapy (saxagliptin + metformin) when compared to placebo + metformin and placebo + saxagliptin with respect to the proportion of subjects requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24 weeks of double-blinded treatment., Baseline to Week 24
|
| Locations: |
Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chuangchun, China|Research Site, Fuzhou, China|Research Site, Guiyang, China|Research Site, Ha'er bin, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shijiazhuang, China|Research Site, Siping, China|Research Site, Tianjin, China|Research Site, Wuxi, China|Research Site, Yueyang, China
|
